Eikonizo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Eikonizo Therapeutics's estimated annual revenue is currently $2.8M per year.
- Eikonizo Therapeutics's estimated revenue per employee is $155,000
- Eikonizo Therapeutics's total funding is $46M.
Employee Data
- Eikonizo Therapeutics has 18 Employees.
- Eikonizo Therapeutics grew their employee count by 20% last year.
Eikonizo Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Head Operations | Reveal Email/Phone |
4 | Executive Director Translational Research | Reveal Email/Phone |
5 | Senior Scientist | Reveal Email/Phone |
6 | Research Scientist II | Reveal Email/Phone |
7 | Scientist II | Reveal Email/Phone |
Eikonizo Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Eikonizo Therapeutics?
Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.
keywords:N/A
$46M
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 18 | -40% | N/A |
#2 | $2.7M | 18 | N/A | N/A |
#3 | $1.6M | 18 | N/A | N/A |
#4 | $1.6M | 18 | 6% | N/A |
#5 | $7.5M | 18 | -14% | N/A |